Key Takeaways:
Adaptive Biotechnologies Corp. reported second-quarter revenue of $71.6 million, beating the $67.2 million consensus estimate, while its per-share loss narrowed more than expected as the immune sequencing company showed progress in its commercial execution.
"The strong revenue performance reflects continued adoption of our clonoSEQ and T-Detect platforms across both pharma and clinical channels," Chief Executive Officer Chad Robins said in a statement.
Revenue rose from the year-ago period, with the company reporting an adjusted loss of 10 cents a share, narrower than the 13.6-cent loss analysts had projected. The beat was driven by higher-than-expected sales in the company's immune medicine segment, which includes its minimal residual disease testing and drug discovery partnerships.
Adaptive Biotechnologies, which uses its immune sequencing platform to develop diagnostics and therapies, has been working to expand the commercial footprint of clonoSEQ, its FDA-cleared test for monitoring minimal residual disease in multiple myeloma and B-cell acute lymphoblastic leukemia patients. The company has also been advancing partnerships with pharmaceutical companies for its T-cell receptor-based drug discovery platform.
The narrower loss and revenue beat come as the company continues to manage operating expenses while scaling its commercial organization. Adaptive has been investing in sales infrastructure to drive adoption of its clinical tests among oncologists and hematologists.
The results signal that Adaptive's commercial strategy is gaining traction as it pushes toward profitability. Investors will watch the company's Q3 earnings call for updates on clonoSEQ test volume trends and any new pharma partnership announcements.
This article is for informational purposes only and does not constitute investment advice.
